Back to Search Start Over

Impact of the Avastin case on prescribing medicines off‐label.

Authors :
Haughey, Sharon
Source :
Prescriber; Sep2019, Vol. 30 Issue 9, p28-31, 4p
Publication Year :
2019

Abstract

In 2018, the High Court ruled that CCGs can prescribe bevacizumab (Avastin) off‐label for wet age‐related macular degeneration (wet AMD). This article discusses the background to the case and its wider implications for drug licensing and clinical practice. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
DRUG laws
BEVACIZUMAB
MEDICAL prescriptions
RETINAL degeneration
DRUG approval
VASCULAR endothelial growth factors
OFF-label use (Drugs)

Details

Language :
English
ISSN :
09596682
Volume :
30
Issue :
9
Database :
Complementary Index
Journal :
Prescriber
Publication Type :
Academic Journal
Accession number :
139252159
Full Text :
https://doi.org/10.1002/psb.1788
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details